Aureolic acid-type anticancer agents, such as mithramycin (MTM) or chromomycin (CMM), are potent anticancer drugs with a unique mode-of-action. They inhibit the growth of cancer cells by cross-linking GC-rich DNA thereby shutting down specificity-protein (Sp)-dependent pathways towards various proto-oncogenes including c-myc and c-src, the latter being associated with the unique hypocalcemic activity found for these drugs. Particularly, MTM is important, and has become a popular biochemical tool to study Sp-dependent signal transduction pathways, but due to its toxic side effects is rarely used as anticancer agent, except for the treatment of tumor hypercalcemia refractory to other chemotherapy. However, MTM was recently identified as a potential lead drug against neurological diseases, arthritis, and for the treatment of hematologic disorders. All these new applications require only very small, less toxic concentrations of the drug, although the mode-of- action in these contexts remains obscure. MTM's biosynthesis has been studied intensely during the previous funding period of this research project, and consequently pursued combinatorial biosynthetic efforts revealed various biosynthetic intermediates and new MTM-analogues. Two of these analogues, MTM SK and MTM SDK, showed a much better anticancer activity profile with a greatly improved therapeutic index than MTM itself. These new drugs deserve further investigations. During the previous biosynthetic studies biosynthetic intriguing and interesting key enzymes were discovered, which need to be further investigated, particularly oxygenase MtmOIV, Ketoreductase MtmW, glycosyltransferases MtmGIV, MtmGIII, MtmGII, MtmGI, and other, early acting post-polyketide synthase tailoring oxygenases and reductases. The goal is to understand the role and mechanisms of these enzymes in the MTM biosynthesis, and to optimize them for the engineering of novel MTM derivatives. It is planned to (a) further investigate unclear biosynthetic steps and mechanisms of the MTM and CMM pathways and to generate new MTM analogues applying combinatorial biosynthesis, (b) to analyze intriguing oxygenases and reductases, (c) to investigate and improve the substrate specificity of glycosyltransferases, (d) to study in vitro and in vivo MTM SK, MTM SDK and other promising MTM analogues developed during the project.

Public Health Relevance

The proposed work aims to develop and refine a new generation of aureolic acid type natural product analogues with significantly diminished toxicity that will be useful mainly as anticancer drugs, but also as drugs to treat neurological diseases, arthritis and hematologic disorders. To enable the production of these fine-tuned drugs through combinatorial biosynthesis, in-depth research of the biosynthetic machinery including key enzymes will be explored.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA091901-10
Application #
8265680
Study Section
Synthetic and Biological Chemistry B Study Section (SBCB)
Program Officer
Fu, Yali
Project Start
2001-06-01
Project End
2013-07-31
Budget Start
2012-06-01
Budget End
2013-07-31
Support Year
10
Fiscal Year
2012
Total Cost
$232,663
Indirect Cost
$66,812
Name
University of Kentucky
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Savi, Daiani C; Shaaban, Khaled A; Vargas, Nathalia et al. (2015) Microbispora sp. LGMB259 endophytic actinomycete isolated from Vochysia divergens (Pantanal, Brazil) producing ?-carbolines and indoles with biological activity. Curr Microbiol 70:345-54
Chen, Jhong-Min; Shepherd, Micah D; Horn, Jamie et al. (2014) Enzymatic methylation and structure-activity-relationship studies on polycarcin V, a gilvocarcin-type antitumor agent. Chembiochem 15:2729-35
Bosserman, Mary A; Downey, Theresa; Noinaj, Nicholas et al. (2013) Molecular insight into substrate recognition and catalysis of Baeyer-Villiger monooxygenase MtmOIV, the key frame-modifying enzyme in the biosynthesis of anticancer agent mithramycin. ACS Chem Biol 8:2466-77
Scott, Daniel; Chen, Jhong-Min; Bae, Younsoo et al. (2013) Semi-synthetic mithramycin SA derivatives with improved anticancer activity. Chem Biol Drug Des 81:615-24
Nybo, S Eric; Shabaan, Khaled A; Kharel, Madan K et al. (2012) Ketoolivosyl-tetracenomycin C: a new ketosugar bearing tetracenomycin reveals new insight into the substrate flexibility of glycosyltransferase ElmGT. Bioorg Med Chem Lett 22:2247-50
Kharel, Madan K; Pahari, Pallab; Shaaban, Khaled A et al. (2012) Elucidation of post-PKS tailoring steps involved in landomycin biosynthesis. Org Biomol Chem 10:4256-65
Pahari, Pallab; Kharel, Madan K; Shepherd, Micah D et al. (2012) Enzymatic total synthesis of defucogilvocarcin M and its implications for gilvocarcin biosynthesis. Angew Chem Int Ed Engl 51:1216-20
Bosserman, Mary A; Florez, Ana B; Shaaban, Khaled A et al. (2011) Characterization of the terminal activation step catalyzed by oxygenase CmmOIV of the chromomycin biosynthetic pathway from Streptomyces griseus. Biochemistry 50:1421-8
Scott, Daniel; Rohr, Jurgen; Bae, Younsoo (2011) Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity. Int J Nanomedicine 6:2757-67
Wang, Guojun; Kharel, Madan K; Pahari, Pallab et al. (2011) Investigating Mithramycin deoxysugar biosynthesis: enzymatic total synthesis of TDP-D-olivose. Chembiochem 12:2568-71

Showing the most recent 10 out of 40 publications